



Theradiag receives Frost & Sullivan 2015 European Theranostics Product Leadership Award during Excellence in Best Practices Awards 2015 ceremony

Croissy-Beaubourg and Montpellier, October 26, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and *in vitro* diagnostics, announced today he received the Frost & Sullivan “2015 European Theranostics Product Leadership Award” during the 2015 Excellence in Best Practices Awards ceremony on Friday October 23rd in Monaco.

The Best Practices Awards are presented each year to companies that are predicted to encourage significant growth in their industries, have identified emerging trends before they became the standard in the marketplace, and have created advanced technologies that will catalyze and transform industries in the near future.

Michel Finance, CEO of Theradiag, comments : *“We are very honored to receive the “2015 European Theranostics Product Leadership Award” that recognizes the innovation and uniqueness of our theranostic solution LISA TRACKER, the market’s most comprehensive range of biotherapy monitoring tools, that allow better adaptation to patients’ treatments through an early prediction and anticipation of response”.*

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of *in vitro* diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer, auto-immune and inflammatory diseases and HIV/AIDS. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 75 employees. For more information about Theradiag, please visit our website: www.theradiag.com



Theradiag
Investor Relations
Nathalie Trepo
+33 1 64 62 10 12
ntrepo@theradiag.com

NewCap
Financial communications/ investor relations
Valentine Brouchet/ Pierre Laurent
+33 1 44 71 94 94
theradiag@newcap.fr

Alize RP
Press
Caroline Carmagnol/ Florence Portejoie
+33 1 44 54 36 64
theradiag@alizerp.com